Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

1220P - A phase III randomized trial investigating preventive effects of perioperative landiolol, a selective beta1 blocker, on the reduction of recurrence of completely resected NSCLC

Date

14 Sep 2024

Session

Poster session 04

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Yasuhiro Hida

Citation

Annals of Oncology (2024) 35 (suppl_2): S775-S793. 10.1016/annonc/annonc1600

Authors

Y. Hida1, J. Suzuki2, M. Endo3, M. TAKAHAMA4, T. Kato5, A. iyoda6, A. Watanabe7, H. Kato8, H. Ito9, T. Murakawa10, T. Nakagawa11, H. Adachi12, M. Mikubo13, K. Asakura14, M. Minami14, T. Kawabata14, H. Yamamoto14, N. Horie15, M. Sato16

Author affiliations

  • 1 Advanced Robotic And Endoscopic Surgery, Fujita Health University, 470-1192 - Toyoake/JP
  • 2 General Thoracic Surgery, Yamagata University Hospital, 990-9585 - Yamagata/JP
  • 3 Department Of Thoracic Surgery, Yamagata Prefectural Central Hospital, 9902292 - Yamagara/JP
  • 4 Department Of General Thoracic Surgery, Osaka City General Hospital, 534-0021 - Osaka/JP
  • 5 Department Of Thoracic Surgery, Hokkaido University Hospital, 060-0812 - Sapporo/JP
  • 6 Division Of Chest Surgery, Department Of Surgery, Toho university, 1438540 - Ota-Ku/JP
  • 7 Department Of Thoracic Surgery, Sapporo Medical University School of Medicine, 060-8543 - Sapporo/JP
  • 8 Department Of Thoracic Surgery, Teine Keijinkai Hospital, 006-8555 - Sapporo/JP
  • 9 Department Of Thoracic Surgery, Kanagawa Cancer Center, 241-8515 - Yokohama/JP
  • 10 Department Of Thoracic Surgery, Kansai Medical University Hospital, 573-101 - Hirakata/JP
  • 11 Department Of Thoracic Surgery, Tenri Hospital, 632-8552 - Nara/JP
  • 12 Department Of Thoracic Surgery, National Hospital Organization, Hokkaido Cancer Center, 003-0804 - Sapporo/JP
  • 13 Department Of Thoracic Surgery, KUSM - Kitasato University School of Medicine, 252-0374 - Sagamihara/JP
  • 14 Department Of Data Science, National Cerebral and Cardiovascular Center, 564-8565 - Suita/JP
  • 15 Clinical Research And Medical Innovation Center, Promotion Unit, Institute Of Health Science Innovation For Medical Care, Hokkaido University Hospital, 060-0812 - Sapporo/JP
  • 16 Institute Of Health Science Innovation For Medical Care, Hokkaido University Hospital, 060-0812 - Sapporo/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1220P

Background

Recent studies have indicated that perioperative use of beta blockers may be associated with prolonged survival in patients (pts) with NSCLC. This study aims to evaluate the preventive effects of landiolol, an ultra-short-acting beta-1-selective blocker, on reducing recurrence of NSCLC after curative surgery.

Methods

This phase III, multicenter, open-label, randomized trial included two parallel groups of pts with NSCLC, comparing surgery alone (S) with surgery combined with continuous infusion of landiolol for 3 days during the perioperative period (L). The primary endpoints were two-year relapse-free survival (RFS) and overall survival (OS).

Results

A total of 404 patients (pts) were enrolled from 12 Japanese institutions, with pts randomized to L (n=197) and S (n=207). The two-year RFS for L and S were 77.2% (95%CI, 71.8 to 83.8) and 78.5% (70.5 to 82.5), respectively. The hazard ratio (HR) for RFS in L was 0.986 (0.639 to 1.522) compared to S, while the HR for OS was 1.339 (0.752 to 2.382). In the safety analysis set population of 392 pts (192 in L and 200 in S), there were no severe adverse events (SAEs) definitively attributed to the study drug. The incidence of adverse events (AEs) leading to discontinuation of the study drug without definitive causality to the study drug was 3.6% (7/192). Adverse events leading to discontinuation of the study drug included bradycardia in 4 pts, sinus bradycardia, bradyarrhythmia, laryngeal edema, recurrent nerve palsy, hypotension, delirium, and injection site extravasation in 1 pt each. AEs leading to death included one case of interstitial lung disease in the L group, which was not causally related to the study drug. Table: 1220P

Inclusion and exclusion criteria of the study

Inclusion criteria Patients may enter the trial if all of the followings apply
Invasive NSCLC is suspected
Complete lobectomy and complete resection including mediastinal lymph node dissection is planned
No synchronous or metachronous (within five years) malignancies, except for carcinoma in situ or mucosal tumors curatively treated with local therapy
Age ≥ 20 years
ECOG PS 0–1
Exclusion criteria Active concurrent malignant diseases
Beta blocker or beta-2 stimulator medication necessary
Preoperative chemotherapy and/or radiotherapy to the target lesion
Contraindicated for the test drug, Landiolol

Conclusions

No significant effect of perioperative landiolol on RFS or OS was observed. Regarding safety, there were no SAEs that definitively correlated with the study drug, and no other notable AEs were observed.

Clinical trial identification

Japan Registry of Clinical Trials, jRCT2011180004, registered 17 January.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Ono Pharmaceutical Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.